Jazz Pharmaceuticals plc — Director's Dealing 2014

Oct 8, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2014-10-06

Reporting Person: ENRIGHT PATRICK G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-10-06	Ordinary Shares	S	2450	$159.4849	Disposed	379889	Indirect
2014-10-06	Ordinary Shares	S	5197	$160.6524	Disposed	374692	Indirect
2014-10-06	Ordinary Shares	S	2157	$161.5743	Disposed	372535	Indirect
2014-10-06	Ordinary Shares	S	49	$159.4737	Disposed	7612	Indirect
2014-10-06	Ordinary Shares	S	104	$160.6506	Disposed	7508	Indirect
2014-10-06	Ordinary Shares	S	43	$161.5653	Disposed	7465	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	3993	Direct

Footnotes

F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $159.03 to $160.01. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $160.25 to $161.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $161.29 to $161.95. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $159.03 to $160.01. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $160.25 to $161.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F6: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $161.29 to $161.95. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F7: The Reporting Person is a managing member of Longitude Capital Partners, LLC, the general partner of each of Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. The Reporting Person disclaims beneficial ownership of the securities of the Issuer held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. except to the extent of his pecuniary interest therein